SPOTLIGHT: Spectrum outlines trial design


Spectrum Pharmaceuticals has reached agreement with the FDA on two late-stage studies of its bladder cancer drug EOquin. The primary goal will be a statistically significant difference in the rate of tumor reoccurrence. Release

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.